Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schiff Nutrition Enlists Airborne For Sortie Into Immune Support

This article was originally published in The Tan Sheet

Executive Summary

The $150 million price represents more than twice Airborne’s approximately $70 million in annual net revenues for supplements marketed to strengthen immune support. The acquisition from GF Capital follows Pfizer’s recent foray into the immune support space by buying the maker of Emergen-C products.

You may also be interested in...



Biopharma Dealmaking Quarterly Statistics, Q4 2012

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

Bayer’s Schiff Nutrition Deal Expands Supplement Portfolio

Bayer Chairman Marijn Dekkers says Schiff’s products will complement its existing nutritionals business and provide marketing synergies with some OTCs. Schiff’s Move Free for joint health, MegaRed for heart health, Airborne for immunity and Digestive Advantage probiotics accounted for 70% of its fiscal 2012 sales.

Bayer’s Schiff Nutrition Deal Expands Supplement Portfolio

Bayer Chairman Marijn Dekkers says Schiff’s products will complement its existing nutritionals business and provide marketing synergies with some OTCs. Schiff’s Move Free for joint health, MegaRed for heart health, Airborne for immunity and Digestive Advantage probiotics accounted for 70% of its fiscal 2012 sales.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS105673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel